Search Results
Your search for ,ARE matches 21445 pages
Showing 12201 - 12250Prostate Cancer Foundation Announces 2017 Young Investigator Awards Recipients
The Prostate Cancer Foundation has announced its 2017 Young Investigator (YI) Awards, which support early-career scientists who are focused on accelerating the delivery of life-extending and life-saving therapies for patients living with prostate cancer. The YI Awards provide 3 years of funding—a...
Maha Hussain, MD, FACP, FASCO, Credits Collaboration for Her Contributions to Genitourinary Cancer
Internationally recognized genitourinary oncologist Maha Hussain, MD, FACP, FASCO, was born and reared in Baghdad, Iraq. “I came from a family that stressed the value of higher education and especially medicine. I have three uncles who are physicians, and my father encouraged my three siblings and...
Journal of Clinical Oncology Literature Update
Staying up-to-date in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology. The topics range from therapy for stage IV non–small cell lung cancer...
Long-Term Follow-up in PIVOT Trial Shows No Significant Benefit of Surgery vs Observation for Overall or Prostate Cancer Mortality
After 19.5 years of follow-up in the PIVOT trial, radical prostatectomy was not associated with significantly improved all-cause or prostate cancer mortality vs observation among men with localized prostate cancer.1 The long-term follow-up was reported in The New England Journal of Medicine by...
Award for Early Career Scientists in New York: Applications Open October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will open for applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000/year—for up to 3 years—to enable them to pursue...
Non–Small Cell Lung Cancer: Emerging Concepts for Checkpoint Inhibitors
With checkpoint inhibitors vitally important in the treatment of advanced non–small cell lung cancer (NSCLC), clinicians must become familiar with the nuances of their use. At the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, Suresh S. Ramalingam, MD,...
‘Sidedness’ in Colon Cancer: Using the Data in the Clinic
The evidence from clinical trials has established that “side matters” when it comes to colorectal cancer outcomes. How do clinicians use this information in their practices? Christina Wu, MD, of Emory University, shared her thoughts with attendees at the 2017 Debates and Didactics in Hematology and ...
Recent FDA Actions Include New Formulation, Expanded Indications for Oncology-Hematology Drug Products
The U.S. Food and Drug Administration (FDA) recently granted approval to olaparib tablets (Lynparza) as a maintenance therapy for ovarian cancer and to inotuzumab ozogamicin (Besponsa), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....
Multiple Myeloma: Researchers Are Digging Deeper Than Ever
Researchers are tackling multiple myeloma from many angles, and the result could be a flood of novel approaches soon within the oncologist’s reach, according to Kenneth C. Anderson, MD. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia, Dr. Anderson...
Targeted Treatments and Health-Related Quality of Life in Ovarian Cancer
Novel targeted treatment strategies and new trial endpoints in recurrent, platinum-sensitive ovarian cancer were highlighted in a gynecologic cancer session at the Best of ASCO New Orleans. At the meeting, Karen McLean, MD, PhD, of the University of Michigan Medical Center, Ann Arbor, presented...
For the Impoverished, Health Care Is a Luxury
Cancer is the second leading cause of death worldwide, and the global burden is on an inexorably upward trajectory. For the year 2012, there were 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide.1 It is predicted that by the year 2035, there will be 23.9 million new...
Long-Term Follow-up of PIVOT Argues for Immediate Treatment of Men With Unfavorable-Risk and Possibly High-Volume, Low-Risk Prostate Cancer
The updated results of the PIVOT1 study—reported in The New England Journal of Medicine by Wilt et al and reviewed in this issue of The ASCO Post—did not show a statistically significant difference between treatment and observation for the initial management approach to men with newly diagnosed...
Update on Hematopoietic Cell Transplant Includes New Data in HIV-Infected and Follicular Lymphoma Patients
New hematology research, presented at the Best of ASCO New Orleans meeting, may help to guide the use of stem cell transplant in hematologic malignancies. At the meeting, Guillermo Garcia-Manero, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and Tycel Phillips, MD, of the...
FDA Clears Mammography Device With Option for Patient-Assisted Compression
On September 1, the U.S. Food and Drug Administration (FDA) cleared the first 2D digital mammography system that allows patients to increase or decrease the amount of compression applied to their own breast before the mammogram x-ray is taken. “Regular mammograms are an important tool in...
FDA Approves Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) today approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) whose tumors express the CD33 antigen. The drug was also approved for the treatment of patients aged 2 years and older with...
Genetic Variant May Significantly Lower Risk of Breast Cancer in Women With History of Preeclampsia
Researchers have demonstrated that women with a history of preeclampsia have as much as a 90% decrease in breast cancer risk if they carry a specific common gene variant. Further studies are now underway to determine the mechanism of this protection in an effort to develop new breast cancer...
Labetuzumab Govitecan in Heavily Pretreated Patients With Metastatic Colorectal Cancer
As reported by Dotan et al in the Journal of Clinical Oncology, the antibody-drug conjugate labetuzumab govitecan showed antitumor activity in a phase I/II trial in patients with heavily pretreated metastatic colorectal cancer who had received prior irinotecan therapy. The agent comprises...
On My Way to Hospice Care, Immunotherapy Saved My Life
Two years ago, I was on my way to hospice care after numerous treatments, including surgery, chemotherapy, and radiation therapy failed to stop the progression of my stage IV castration-resistant prostate cancer. A last-minute call from my oncologist about a phase I trial of combination...
FDA Statement Regarding Safety Concerns Related to Investigational Use of Pembrolizumab in Multiple Myeloma
On August 31, U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research Director Janet Woodcock, MD, issued the following statement: “Clinical trials play a critically important role in bringing to market innovative new therapies for patients facing life-threatening...
ASCO Publishes Resources for Cancer Care Providers and Patients Affected by Hurricane Harvey
In the aftermath of the devastation caused by Hurricane Harvey throughout the state of Texas, which has resulted in more than 30,000 people being displaced from their homes, ASCO has published a list of resources and information for oncology providers and patients with cancer affected by the...
Artificial Intelligence May Help With Earlier Detection of Skin Cancer
New technology being developed by researchers at the University of Waterloo and the Sunnybrook Research Institute is using artificial intelligence (AI) to help detect melanoma at earlier stages. The technology employs machine-learning software to analyze images of skin lesions and provide...
Adipose Tissue and Cancer Risk
Although obesity and its associated metabolic dysregulation are established risk factors for many cancers, the biologic mechanisms underlying this relationship are not well understood. Now, the results from a systematic literature review by Himbert et al of human clinical studies exploring the...
FDA Approves First CAR T-Cell Therapy for Pediatric and Young Adult Patients With B-Cell Precursor ALL
Today, the U.S. Food and Drug Administration (FDA) issued what it has called a “historic action,” making the first gene therapy available in the United States. The FDA approved tisagenlecleucel (Kymriah) for certain pediatric and young adult patients with a form of acute lymphoblastic...
Tivozanib Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
On August 28, AVEO Oncology announced that the European Commission (EC) has approved tivozanib (Fotivda) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland. Tivozanib is indicated for the first-line treatment of adult patients with...
Phase III ALCYONE Study of Daratumumab in Front-Line Treatment of Multiple Myeloma
On August 24, positive topline results were announced from the phase III ALCYONE study of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) vs VMP alone as front-line treatment for newly diagnosed patients who are not considered candidates for...
Association of Systemic Inflammation and Sarcopenia With Survival in Early-Stage Colorectal Cancer
Results from the C SCANS (Colorectal Cancer: Sarcopenia, Cancer, and Near-Term Survival) study indicate that prediagnosis systemic inflammation and at-diagnosis sarcopenia are associated with an increased mortality risk in patients with nonmetastatic colorectal cancer. The findings were reported in ...
FDA Accepts sBLA, Grants Priority Review for Obinutuzumab in Previously Untreated Follicular Lymphoma
On August 28, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for obinutuzumab (Gazyva) in combination with chemotherapy followed by obinutuzumab alone for patients with previously untreated follicular lymphoma....
2018 Pershing Square Sohn Cancer Research Prize Opens for Applications on October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will begin accepting applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000 per year—for up...
FDA Approves Fulvestrant as Monotherapy for Expanded Use in Breast Cancer
On August 28, the U.S. Food and Drug Administration (FDA) approved fulvestrant (Faslodex) at 500 mg as monotherapy for expanded use in women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who have gone through menopause...
HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors
The rate of human papillomavirus (HPV) vaccination in the United States is increasing, but remains lower than ideal. A new study suggests that survivors of childhood cancer receive the HPV vaccine at an even lower rate than their peers without cancer—24% vs 40%, respectively. Nearly...
Palliative Care May Substantially Decrease Health-Care Utilization in Patients With Advanced Cancer
A new population-based study shows that palliative care substantially decreased health-care utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures,...
Women More Likely Than Men to Experience Response After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer
Female patients with locally advanced esophageal cancer treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published by...
Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers
Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2 mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance to a common...
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
As reported in the Journal of Oncology Practice by Chang et al, for the first time for any type of malignancy, the American Urological Association (AUA), ASCO, American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have formulated an evidence-based guideline on...
Use of CD4-Positive T Cells With MHC Class II–Restricted Receptors Targeting MAGE-A3 in Metastatic Cancer
In a study reported in the Journal of Clinical Oncology, Lu et al found that autologous CD4-positive T cells engineered to express a major histocompatibility complex (MHC) class II–restricted T-cell receptor (TCR) targeting the cancer germline antigen MAGE-A3 (melanoma-associated antigen-A3)...
African American Men Have Lowest Survival Rates Among Patients With Anal Cancer
Over the past 30 years, squamous cell carcinoma of the anus has been one of the few cancers with a steadily rising incidence in the United States, with the most rapid increase seen in black men. To further investigate this trend, researchers at the University of Texas Southwestern Medical Center...
Nodal Stage Migration and Prognosis in Anal Cancer
In a study reported in The Lancet Oncology, Sekhar et al found that the increasing proportion of lymph node–positive disease associated with enhanced detection techniques has led to nodal stage migration in anal cancer, which may reduce prognostic discrimination on the basis of lymph node...
Prolonged and Intensified Neoadjuvant Therapy for Esophageal Adenocarcinoma
A UK phase III trial (UK MRC OE05) has shown no significant survival benefit of extended and intensified neoadjuvant chemotherapy with epirubicin, cisplatin, and capecitabine vs standard cisplatin/fluorouracil followed by resection in patients with esophageal adenocarcinoma. The findings were...
Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative Breast Cancer: A Step in the Right Direction
IN A SINGLE-ARM multicenter trial reported by Bardia and colleagues1 and reviewed in this issue of The ASCO Post, the use of sacituzumab govitecan (IMMU-132) showed a response rate of 30% and a clinical benefit rate of 46% in heavily pretreated patients with metastatic triple-negative breast...
AKT Inhibitor Ipatasertib in Metastatic Triple-Negative Breast Cancer
The randomized phase II LOTUS trial has shown improved progression-free survival with the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of metastatic triple-negative breast cancer. These results were reported by Kim et al in The Lancet Oncology. The PI3K/AKT...
Early-Phase Study Finds Vitamin C May Activate TET2 Function
Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published by Cimmino et al in Cell....
Comparison of Screening Recommendations for Mammography
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening...
Reagan-Udall Foundation for the FDA Launches Expanded Access Navigator Website
THE NONPROFIT Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) has released a new online resource called the Expanded Access Navigator. The website, which focuses on oncology, features the first pharmaceutical company directory of expanded access policies and criteria, as...
ASCO Offers Path to Addressing Affordability of Cancer Drugs
ASCO RECENTLY issued a position statement on rising cancer drug prices. The statement, asserting that solutions to address the affordability of cancer drugs must also preserve patients’ access to care and foster innovation, analyzes a wide array of options and recommends that a panel of...
Charting the Future of Cancer Health Disparities Research
LEADING NATIONAL cancer organizations have released a joint position statement1 to guide the future of cancer health disparities research. The statement represents a unified strategy by ASCO, the American Association for Cancer Research, the American Cancer Society, and the National Cancer...
ASCO, CCF Congratulate 2017 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.3 million in grants and awards to 247 promising oncology researchers at the 2017 ASCO Annual Meeting. CCF and ASCO congratulate the recipients on their contributions to the field of oncology and offer their profound thanks to the...
Detection of Early-Stage Cancers With Circulating Tumor DNA
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...
Adding First-Line Selective Internal Radiotherapy to Chemotherapy in Patients With Liver Metastases From Colorectal Cancer
A meta-analysis of three randomized trials (FOXFIRE, SIRFLOX, and FOXFIRE-Global) indicates no overall survival benefit of adding first-line selective internal radiotherapy to chemotherapy in patients with liver metastases from colorectal cancer. The findings were reported by Wasan et al in The...
Crizotinib in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
In a Children’s Oncology Group study, high response rates were achieved with crizotinib (Xalkori) treatment in pediatric ALK-positive anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors. These results were reported by Mossé et al in the Journal of Clinical...
Carlos L. Arteaga, MD, Named Director of UT Southwestern Cancer Center
CARLOS L. ARTEAGA, MD, has been named Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at The UT Southwestern Medical Center in Dallas. Roles and Research at Vanderbilt DR. ARTEAGA IS CURRENTLY Director of the Center for Cancer Targeted...
